Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
ORIC Analyst Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ORIC Stock 12 Month Forecast
Average Price Target
$19.13
▲(67.95% Upside)
| Highest Price Target$25.00 | Average Price Target$19.13 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$20
Buy
75.59%
Upside
Reiterated
12/05/25
Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals' EnozertinibWe note that ArriVent's (AVBP, BUY, $45 PT) firmonertinib is currently in the lead in 1L PACC mutated NSCLC, with mPFS of 16.0 months in a Phase 1b trial (n=22; WCLC 2025) and an ongoing Phase 3 trial (ALPACCA). Please see pages 3–7 below for a summary of clinical data in atypical and EGFR PACC-mutated NSCLC (Exhibits 1–4), along with key data from ORIC’s presentation.
Wedbush
$20
Buy
75.59%
Upside
Reiterated
12/04/25
J.P. Morgan
―
Buy
―
Reiterated
12/03/25
Evercore ISI
$25
Buy
119.49%
Upside
Initiated
11/20/25
Promising Potential of Oric Pharmaceuticals' ORIC-944 in Prostate Cancer Market Drives Buy RatingWe see a compelling oppy for ORIC, positioned to compete in the large prostate cancer market. Lead asset ORIC-944 has the potential to bring a highly effective oral agent across multiple settings. The MOA is validated by PFE’s mevrometostat, which has shown promising randomized data. Given the vast market and the historical successes from other drugs in the space, we see a favorable risk-reward setup at current levels. Key catalyst in 1Q26 should further inform the ultimate opportunity.
Citi
$12→$16
Buy
40.47%
Upside
Reiterated
11/17/25
H.C. Wainwright
$19→$23
Buy
101.93%
Upside
Reiterated
11/17/25
Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price TargetValuation and Risks. We value ORIC utilizing a discounted cash flow (DCF)-based valuation methodology. Our assumptions include a 12% discount rate, 1% terminal growth rate, and 35% probability of approval for ORIC-114 in EGFR exon 20 insertion- positive non-small cell lung cancer (NSCLC) and a 40% probability of approval for ORIC-944 in mCRPC. This set of parameters yields a price objective of $23 per share.
Wells Fargo
$20→$19
Buy
66.81%
Upside
Reiterated
11/14/25
Ladenburg Thalmann & Co.
$15
Buy
31.69%
Upside
Reiterated
11/14/25
Oppenheimer
$12→$15
Buy
31.69%
Upside
Reiterated
11/14/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/26/25
Guggenheim
$18
Buy
58.03%
Upside
Initiated
09/03/25
Oric Pharmaceuticals' ORIC-944: A Promising PRC2 Inhibitor with Strategic Partnerships and Market PotentialWe are assuming coverage of ORIC Pharmaceuticals, Inc. (ORIC) from Michael Schmidt and assigning a Buy rating and $18 price target. We like a fast-follower oncology thesis if there's a near-term data catalyst that will benefit all players by further validating the class and a pitch about why the follower could be better in certain ways or situations to plausibly model market share for it. We see both these elements for ORIC's lead drug ORIC-944, a PRC2 inhibitor that follows PFE's mevrometostat with its strong randomized mCRPC phase 2 data and imminent first phase 3 readouts. This class has broken all the rules in terms of PSA correlation to rPFS (there may be a biology reason for this), but we support development when a randomized phase 2 rPFS effect size is as large as the 0.51 HR demonstrated by mevrometostat.
Jefferies
$22→$23
Buy
101.93%
Upside
Reiterated
08/13/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$20
Buy
75.59%
Upside
Reiterated
12/05/25
Promising Clinical Data and Market Potential Drive Buy Rating for Oric Pharmaceuticals' EnozertinibWe note that ArriVent's (AVBP, BUY, $45 PT) firmonertinib is currently in the lead in 1L PACC mutated NSCLC, with mPFS of 16.0 months in a Phase 1b trial (n=22; WCLC 2025) and an ongoing Phase 3 trial (ALPACCA). Please see pages 3–7 below for a summary of clinical data in atypical and EGFR PACC-mutated NSCLC (Exhibits 1–4), along with key data from ORIC’s presentation.
Wedbush
$20
Buy
75.59%
Upside
Reiterated
12/04/25
J.P. Morgan
―
Buy
―
Reiterated
12/03/25
Evercore ISI
$25
Buy
119.49%
Upside
Initiated
11/20/25
Promising Potential of Oric Pharmaceuticals' ORIC-944 in Prostate Cancer Market Drives Buy RatingWe see a compelling oppy for ORIC, positioned to compete in the large prostate cancer market. Lead asset ORIC-944 has the potential to bring a highly effective oral agent across multiple settings. The MOA is validated by PFE’s mevrometostat, which has shown promising randomized data. Given the vast market and the historical successes from other drugs in the space, we see a favorable risk-reward setup at current levels. Key catalyst in 1Q26 should further inform the ultimate opportunity.
Citi
$12→$16
Buy
40.47%
Upside
Reiterated
11/17/25
H.C. Wainwright
$19→$23
Buy
101.93%
Upside
Reiterated
11/17/25
Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price TargetValuation and Risks. We value ORIC utilizing a discounted cash flow (DCF)-based valuation methodology. Our assumptions include a 12% discount rate, 1% terminal growth rate, and 35% probability of approval for ORIC-114 in EGFR exon 20 insertion- positive non-small cell lung cancer (NSCLC) and a 40% probability of approval for ORIC-944 in mCRPC. This set of parameters yields a price objective of $23 per share.
Wells Fargo
$20→$19
Buy
66.81%
Upside
Reiterated
11/14/25
Ladenburg Thalmann & Co.
$15
Buy
31.69%
Upside
Reiterated
11/14/25
Oppenheimer
$12→$15
Buy
31.69%
Upside
Reiterated
11/14/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/26/25
Guggenheim
$18
Buy
58.03%
Upside
Initiated
09/03/25
Oric Pharmaceuticals' ORIC-944: A Promising PRC2 Inhibitor with Strategic Partnerships and Market PotentialWe are assuming coverage of ORIC Pharmaceuticals, Inc. (ORIC) from Michael Schmidt and assigning a Buy rating and $18 price target. We like a fast-follower oncology thesis if there's a near-term data catalyst that will benefit all players by further validating the class and a pitch about why the follower could be better in certain ways or situations to plausibly model market share for it. We see both these elements for ORIC's lead drug ORIC-944, a PRC2 inhibitor that follows PFE's mevrometostat with its strong randomized mCRPC phase 2 data and imminent first phase 3 readouts. This class has broken all the rules in terms of PSA correlation to rPFS (there may be a biology reason for this), but we support development when a randomized phase 2 rPFS effect size is as large as the 0.51 HR demonstrated by mevrometostat.
Jefferies
$22→$23
Buy
101.93%
Upside
Reiterated
08/13/25
Best Analysts Covering Oric Pharmaceuticals
1 Month
xxx
Success Rate
9/15 ratings generated profit
Average Return
+8.65%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +8.65% per trade.
3 Months
xxx
Success Rate
9/15 ratings generated profit
Average Return
+8.43%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +8.43% per trade.
1 Year
Success Rate
15/20 ratings generated profit
Average Return
+26.74%
reiterated a buy rating 19 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +26.74% per trade.
2 Years
xxx
Success Rate
9/11 ratings generated profit
Average Return
+31.15%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +31.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ORIC Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
6
6
7
10
9
Buy
3
5
6
7
6
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
11
13
18
16
Each month's total comprises the sum of three months' worth of ratings.
ORIC Financial Forecast
ORIC Stock Forecast FAQ
What is ORIC’s average 12-month price target, according to analysts?
Based on analyst ratings, Oric Pharmaceuticals’s 12-month average price target is 19.13.
What is ORIC’s upside potential, based on the analysts’ average price target?
Oric Pharmaceuticals has 67.95% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ORIC a Buy, Sell or Hold?
Oric Pharmaceuticals has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is Oric Pharmaceuticals’s price target?
The average price target for Oric Pharmaceuticals is 19.13. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $15.00. The average price target represents 67.95% Increase from the current price of $11.39.
The highest analyst price target is $25.00 ,the lowest forecast is $15.00. The average price target represents 67.95% Increase from the current price of $11.39.
What do analysts say about Oric Pharmaceuticals?
Oric Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of ORIC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.